Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AE Protease inhibitors
J05AE08 Atazanavir
D01276 Atazanavir sulfate (JAN/USAN) <US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Agents, Protease Inhibitors (PI)
Atazanavir
D01276 Atazanavir sulfate (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D01276 Atazanavir sulfate (JAN/USAN)
Drug groups [BR:br08330]
Antiviral
DG03107 Anti-HIV agent
DG01647 HIV protease inhibitor
DG00657 Atazanavir
D01276 Atazanavir sulfate
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
DG00657 Atazanavir
D01276 Atazanavir sulfate
DG02887 UGT1A1 inhibitor
DG00657 Atazanavir
D01276 Atazanavir sulfate
Drug classes [BR:br08332]
Antiviral
DG03107 Anti-HIV agent
D01276 Atazanavir sulfate
Antimicrobials [BR:br08307]
Antivirals
Polyprotein cleavage inhibitor
HIV protease inhibitor
D01276 Atazanavir sulfate (JAN/USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01276
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01276
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01276
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01276
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01276
Drug groups [BR:br08330]
Antiviral
DG03107 Anti-HIV agent
DG01647 HIV protease inhibitor
DG00657 Atazanavir
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
DG00657 Atazanavir
DG02887 UGT1A1 inhibitor
DG00657 Atazanavir
Antimicrobials abbreviations [BR:br08327]
Antivirals
Polyprotein cleavage inhibitor
HIV protease inhibitor
DG00657 Atazanavir